Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 43

1.
2.

Perspectives for cancer therapies with cdk2 inhibitors.

Wadler S.

Drug Resist Updat. 2001 Dec;4(6):347-67. Review.

PMID:
12030783
3.

Chemical and biological profile of dual Cdk1 and Cdk2 inhibitors.

Ruetz S, Fabbro D, Zimmermann J, Meyer T, Gray N.

Curr Med Chem Anticancer Agents. 2003 Jan;3(1):1-14. Review.

PMID:
12678910
4.

Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms.

Senderowicz AM.

Cancer Chemother Pharmacol. 2003 Jul;52 Suppl 1:S61-73. Epub 2003 Jun 18. Review.

PMID:
12819936
5.

The role of cyclin E in cell proliferation, development and cancer.

Keyomarsi K, Herliczek TW.

Prog Cell Cycle Res. 1997;3:171-91. Review.

PMID:
9552414
6.
7.

Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials.

Senderowicz AM.

Invest New Drugs. 1999;17(3):313-20. Review.

PMID:
10665481
8.

Structure-based design of cyclin-dependent kinase inhibitors.

Davies TG, Pratt DJ, Endicott JA, Johnson LN, Noble ME.

Pharmacol Ther. 2002 Feb-Mar;93(2-3):125-33. Review.

PMID:
12191605
9.

Centrosome aberrations and cancer.

Krämer A, Ho AD.

Onkologie. 2001 Dec;24(6):538-44. Review.

PMID:
11799308
10.

Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol.

Shapiro GI.

Clin Cancer Res. 2004 Jun 15;10(12 Pt 2):4270s-4275s. Review.

12.

Small molecule modulators of cyclin-dependent kinases for cancer therapy.

Senderowicz AM.

Oncogene. 2000 Dec 27;19(56):6600-6. Review.

13.

Cyclin-dependent kinase modulators studied at the NCI: pre-clinical and clinical studies.

Sausville EA.

Curr Med Chem Anticancer Agents. 2003 Jan;3(1):47-56. Review.

PMID:
12678914
14.

Anticancer drug targets: cell cycle and checkpoint control.

Shapiro GI, Harper JW.

J Clin Invest. 1999 Dec;104(12):1645-53. Review. No abstract available.

15.

Review of flavopiridol, a cyclin-dependent kinase inhibitor, as breast cancer therapy.

Tan AR, Swain SM.

Semin Oncol. 2002 Jun;29(3 Suppl 11):77-85. Review.

PMID:
12138401
16.

Structural basis for substrate recognition and control in protein kinases.

Johnson LN.

Ernst Schering Res Found Workshop. 2001;(34):47-69. Review. No abstract available.

PMID:
11394047
17.
18.

Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development.

Zhai S, Senderowicz AM, Sausville EA, Figg WD.

Ann Pharmacother. 2002 May;36(5):905-11. Review.

PMID:
11978170
19.

Cell cycle modulators for the treatment of lung malignancies.

Senderowicz AM.

Clin Lung Cancer. 2003 Nov;5(3):158-68. Review.

PMID:
14667271
20.

Cyclin-dependent kinase pathways as targets for cancer treatment.

Shapiro GI.

J Clin Oncol. 2006 Apr 10;24(11):1770-83. Review.

PMID:
16603719

Supplemental Content

Support Center